Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $115 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a price target of $115.
July 22, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Ultragenyx Pharmaceutical and maintained a price target of $115, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $115 by a reputable analyst suggests positive sentiment and confidence in Ultragenyx Pharmaceutical's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100